BioMarin Pharmaceutical Inc.
About BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company dedicated to transforming lives through genetic discovery. In 1997, the company was founded to make a big difference in small patient populations, focusing on giving much-needed attention to the underserved communities of those with rare diseases. BioMarin sought to help patients whose voices could not always be heard and treat conditions that were not always in mainstream medical conversations. Throughout its history, BioMarin has worked tirelessly to make a difference by pursuing bold science. The company’s first approved therapy was inspired by a father who refused to accept there was no therapy for his son’s rare diagnosis. That relentless pursuit to change the course of his son’s future through the power of science is at the core of who BioMarin is today.
Through the company’s expertise in genetics and molecular biology, BioMarin has developed eight first or best-in-class targeted therapies that address the root cause of the conditions it seeks to treat, helping to better the lives of those struggling with rare genetic disease. The company’s purposeful and scientifically precise team of physicians and scientists has honed each treatment modality to seek transformative therapies.
Now, BioMarin seeks to make an even greater impact by applying the same science-driven, patient-forward approach that propelled the last 25 plus years of drug development to larger genetic disorders, as well as genetic subsets of more common conditions. Each drug candidate pursued is guided by a fundamental understanding of the genetics and underlying biology of the condition it will address. The company believes that applying its knowledge to make a transformative impact is not just a calling, but an obligation to those who will benefit most. The more innovative solutions developed, the more lives BioMarin can impact.
803 articles with BioMarin Pharmaceutical Inc.
-
BioMarin Pharmaceutical Inc. To Present At The Cowen And Company 7th Annual Global Healthcare Conference
11/3/2006
-
BioMarin Pharmaceutical Inc. Announces Third Quarter 2006 Financial Results
11/2/2006
-
BioMarin Pharmaceutical Inc. To Present At The Rodman And Renshaw 8th Annual Healthcare Conference
11/1/2006
-
BioMarin Pharmaceutical Inc. Announces Marketing Approval For Aldurazyme In Japan
11/1/2006
-
BioMarin Pharmaceutical Inc. To Host Third Quarter 2006 Earnings Call And Webcast On Wednesday, November 1 At 5:00 P.M. ET (23:00 CET)
10/26/2006
-
BioMarin Pharmaceutical Inc. Completes Partial Exchange Of Convertible Notes Due 2008 For Common Stock
9/25/2006
-
BioMarin Pharmaceutical Inc. Completes Enrollment Of Phase 2 Clinical Study Of 6R-BH4 In Poorly Controlled Hypertension
9/21/2006
-
BioMarin Pharmaceutical Inc. And Serono, Inc. Announce Data On Phenoptin In PKU To Be Presented At The 56th Annual Meeting Of The American Society of Human Genetics
9/12/2006
-
The Day In Review: Genentech, Inc. Casts A Pall Over Biotech
9/11/2006
-
BioMarin Pharmaceutical Inc. Provides Update On Phenylase Product Development
9/11/2006
-
BioMarin Pharmaceutical Inc. Announces U.S. Launch of Orapred ODT Through ALLIANT Pharmaceuticals, Inc.
8/28/2006
-
BioMarin Pharmaceutical Inc. Announces Second Quarter 2006 Financial Results
8/3/2006
-
BioMarin Pharmaceutical Inc. To Host Second Quarter 2006 Earnings Call And Webcast On Wednesday, August 2 At 5:00 P.M. ET (23:00 CEST)
7/27/2006
-
The Week In Review: Bayer Buys Diabetes Device Maker
7/7/2006
-
BioMarin Pharmaceutical Inc. Initiates Phase 2 Clinical Study Of 6R-BH4 In Poorly Controlled Hypertension
7/6/2006
-
CIMA LABS INC. Drug Delivery Technology Used In Orapred ODT(TM)
6/19/2006
-
BioMarin Pharmaceutical Inc. To Present At The 2006 Pacific Growth Equities Life Sciences Growth Conference
6/6/2006
-
BioMarin Pharmaceutical Inc. And ALLIANT Pharmaceuticals, Inc. Announce FDA Approval Of Orapred ODT
6/2/2006
-
BioMarin Pharmaceutical Inc. To Present At The Bear Biotech Boston Confab
5/25/2006
-
BioMarin Pharmaceutical Inc. To Present At The Rodman And Renshaw 3rd Annual Global Healthcare Conference
5/8/2006